---
title: "Why Is GH Research Stock Trading Higher on Thursday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292932378.md"
description: "GH Research and Definium Therapeutics stocks rose following Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion. GH Research shares surged 11.40% as its lead drug GH001 draws comparisons to AtaiBeckley’s BPL-003, particularly regarding treatment-resistant depression applications and recent FDA clearance."
datetime: "2026-07-16T16:36:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292932378.md)
  - [en](https://longbridge.com/en/news/292932378.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292932378.md)
generator: "portal-rs"
---

# Why Is GH Research Stock Trading Higher on Thursday?

**GH Research PLC** (NASDAQ:GHRS) and **Definium Therapeutics Inc.** (NASDAQ:DFTX) stocks are trading higher in response to **Eli Lilly and Co.** (NYSE:LLY) agreeing to acquire **AtaiBeckley Inc**. (NASDAQ:ATAI) in a deal valued at up to $3.80 billion.

Bloomberg was the first to report the deal. AtaiBeckley is one of several companies poised to usher in this new era of psychedelics.

 **Read Also: Depression-Focused GH Research Shares Could See Significant Upside: Analyst** 

## GH001 Draws Comparisons With AtaiBeckley’s Lead Drug Candidate

GH Research’s lead drug, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach, similar to AtaiBeckley’s lead asset, BPL-003 (mebufotenin benzoate), administered intranasally for treatment-resistant depression.

## Prior Data Supports Treatment-Resistant Depression Program

In March 2026, the results of the Phase 2b trial in TRD (GH001-TRD-201) were published in JAMA Psychiatry.

A post-hoc analysis reported alongside the publication demonstrated efficacy independent of the number of prior antidepressant treatment failures, with Day 8 remission rates of 53.9%-63.6% across subgroups.

In May, GH Research said it completed enrolment in a Phase 1 pharmacology trial in the U.K., evaluating a proprietary aerosol delivery device for the administration of GH001 in healthy volunteers (GH001-HV-106).

The company selected the doses for the global Phase 3 pivotal program based on the results from this trial for treatment-resistant depression.

In January, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research’s Investigational New Drug Application (IND) for GH001 after the FDA placed a clinical hold in September 2023 due to insufficient information to assess risks to human subjects.

## Shorter Treatment Duration For BPL-003

Bloomberg’s report on Thursday noted that BPL-003’s shorter treatment duration is a key advantage.

Its psychedelic effects last about one to two hours, compared with some experimental therapies, including one from **Compass Pathways Plc** (NASDAQ:CMPS), that may require patient monitoring for up to eight hours.

**Price Action:** GH Research shares were up 11.40% at $29.99, and Definium Therapeutics shares were down 1.31% at $45.06 at the time of publication on Thursday, according to Benzinga Pro data.

 **Read Also: Publix Closes More Stores in 2026 as Walmart Competition, Rising Costs and Online Grocery Shopping Bite: Here are the Locations Affected** 

*Photo: Shutterstock*

### Related Stocks

- [GHRS.US](https://longbridge.com/en/quote/GHRS.US.md)
- [ATAI.US](https://longbridge.com/en/quote/ATAI.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)
- [WMT.US](https://longbridge.com/en/quote/WMT.US.md)

## Related News & Research

- [Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.](https://longbridge.com/en/news/297565544.md)
- [Benjamin Edwards Inc. Has $34.94 Million Stake in Eli Lilly and Company $LLY](https://longbridge.com/en/news/298002862.md)
- [Eli Lilly's Taltz-Zepbound Combo Shows Encouraging Results At Week 52](https://longbridge.com/en/news/297510647.md)
- [Lilly's $9.94 Billion Mounjaro Franchise Wins a Heart-Risk Label](https://longbridge.com/en/news/297356212.md)
- [Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs](https://longbridge.com/en/news/297082109.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**